Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
-
Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed
-
Imfinzi approved in China for the treatment of unresectable, Stage III non-small cell lung cancer based on the Phase III PACIFIC trial
-
Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
-
Calquence significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukaemia
-
Lynparza approved in China as a 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer
-
AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
-
Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
-
Calquence approved in the US for adult patients with chronic lymphocytic leukaemia
-
Harvard Business Review names Pascal Soriot among ‘Best Performing Top 100 CEOs in the World’ 2019
Latest articles and press releases
All of our latest press releases and articles are available to explore
